DPP4 and COVID-19: Therefore, we are trying to conduct a meta-analysis to provide high-quality evidence for the treatment of COVID-19 diabetes patients with DPP-4 inhibitors, and to inject new impetus into the clinical response to the COVID-19 epidemic.